Lenvatinib trial offers hope for thyroid cancer patients

February 12, 2015 8:45 PM

2 0

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131.

In a clinical trial of almost 400 patients from 21 different countries, patients who took lenvatinib survived for a median of 18.3 months without displaying any signs of disease progression, while those who were given placebo only had a median progression-free survival of 3.6 months.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...